+

WO2004056971A3 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers - Google Patents

Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers Download PDF

Info

Publication number
WO2004056971A3
WO2004056971A3 PCT/US2003/041433 US0341433W WO2004056971A3 WO 2004056971 A3 WO2004056971 A3 WO 2004056971A3 US 0341433 W US0341433 W US 0341433W WO 2004056971 A3 WO2004056971 A3 WO 2004056971A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
antisense oligomers
present
disorder
antisense
Prior art date
Application number
PCT/US2003/041433
Other languages
French (fr)
Other versions
WO2004056971A2 (en
Inventor
Raymond P Warrell
Original Assignee
Genta Inc
Raymond P Warrell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,717 external-priority patent/US20040147473A1/en
Priority claimed from US10/738,867 external-priority patent/US7855183B2/en
Application filed by Genta Inc, Raymond P Warrell filed Critical Genta Inc
Priority to AU2003300414A priority Critical patent/AU2003300414A1/en
Publication of WO2004056971A2 publication Critical patent/WO2004056971A2/en
Publication of WO2004056971A3 publication Critical patent/WO2004056971A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
PCT/US2003/041433 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers WO2004056971A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300414A AU2003300414A1 (en) 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US43505702P 2002-12-19 2002-12-19
US43502902P 2002-12-19 2002-12-19
US60/435,029 2002-12-19
US60/435,057 2002-12-19
US10/738,717 2003-12-16
US10/738,717 US20040147473A1 (en) 2000-11-10 2003-12-16 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US10/738,867 US7855183B2 (en) 2000-11-10 2003-12-16 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US10/738,867 2003-12-16

Publications (2)

Publication Number Publication Date
WO2004056971A2 WO2004056971A2 (en) 2004-07-08
WO2004056971A3 true WO2004056971A3 (en) 2005-03-10

Family

ID=32686284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041433 WO2004056971A2 (en) 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Country Status (2)

Country Link
AU (1) AU2003300414A1 (en)
WO (1) WO2004056971A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
US7524827B2 (en) * 2004-06-01 2009-04-28 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
ES2419106T3 (en) 2005-12-01 2013-08-19 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP3000480A1 (en) * 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
WO2014071406A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
ES2731377T3 (en) 2015-07-07 2019-11-15 Hoffmann La Roche Polytherapy with an anti-HER2-drug antibody conjugate and a bcl-2 inhibitor
WO2017021963A1 (en) 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHESON B.D.: "Hematologic malignancies: new developments and future treatments", SEMINARS IN ONCOLOGY, vol. 29, no. 4 SUPPLEMENT 13, August 2002 (2002-08-01), pages 33 - 45, XP008041699 *
JANSEN ET AL.: "Chemosensitisation of malignant melanoma by BCL2 antisense therapy", THE LANCET, vol. 356, 2000, pages 1728 - 1733, XP004264208 *
KOSMIDIS ET AL.: "Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study: Hellenic cooperative oncology group for lung cancer trials", SEMINARS IN ONCOLOGY, vol. 21, no. 3 SUPPLEMENT 6, June 1994 (1994-06-01), pages 23 - 30, XP008041700 *
LOPES DE MENEZES ET AL.: "Molecular and pharmacokinetic properties associated with therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin", CLINICAL CANCER RESEARCH, vol. 6, 2000, pages 2891 - 2902, XP002982934 *
MIAYAKE ET AL.: "Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense bcl-2 oligonucleotides", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 92, 2000, pages 34 - 41, XP000964815 *
TOLCHER ET AL.: "Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer", SEMINARS IN ONCOLOGY, vol. 28, no. 4 SUPPLEMENT 15, August 2001 (2001-08-01), pages 67 - 70, XP009004603 *

Also Published As

Publication number Publication date
WO2004056971A2 (en) 2004-07-08
AU2003300414A1 (en) 2004-07-14
AU2003300414A8 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2002017852A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
MXPA03010121A (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents.
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1123741A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine)
MY112405A (en) Method of tumer treatment.
DK1165108T3 (en) Use of an extract of Serenoa repens for the manufacture of a drug for the treatment of prostate cancer
EP1455840A4 (en) Treatment of human cancer with adenoviral vector expressing tnf-alpha
WO2002057480A3 (en) Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
GB0020504D0 (en) Therapeutic method
DE60116075D1 (en) TREATMENT OF TUMORS WITH PHOTODYNAMIC THERAPY
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
ATE354373T1 (en) ADMINISTRATION OF GAMMAGLOBULINS FOR THE TREATMENT OF LYMPHOMAS
WO2002026754A3 (en) Oligonucleotides, agents containing these oligonucleotides, and the use thereof
WO2004017919A3 (en) Use of mullerian inhibiting substance and interferon for treating tumors
CR6932A (en) METHODS OF TREATMENT OF A BCL-2 DISORDER USING BIG-2 ANTISENT OLIGOMERS.
EA200600987A1 (en) APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载